Genes, Vol. 12, Pages 1593: Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers
Genes, Vol. 12, Pages 1593: Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers
Genes doi: 10.3390/genes12101593
Authors:
Yun-Hsin Tang
Chiao-Yun Lin
Chyong-Huey Lai
With the advent of next-generation sequencing (NGS), The Cancer Genome Atlas (TCGA) research network has given gynecologic cancers molecular classifications, which impacts clinical practice more and more. New cancer treatments that identify and target pathogenic abnormalities of genes have been in rapid development. The most prominent progress in gynecologic cancers is the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors, which have shown breakthrough benefits in reducing hazard ratios (HRs) (HRs between 0.2 and 0.4) of progression or death from BRCA1/2 mutated ovarian cancer. Immune checkpoint inhibition is also promising in cancers that harbor mismatch repair deficiency (dMMR)/microsatellite instability (MSI). In this review, we focus on the druggable genetic alterations in gynecologic cancers by summarizing literature findings and completed and ongoing clinical trials.
Source: Genes - Category: Genetics & Stem Cells Authors: Yun-Hsin Tang Chiao-Yun Lin Chyong-Huey Lai Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Gastroschisis Repair | Genetics | Ovarian Cancer | Ovaries